Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

XLV vs. FTXH: which is better?

Bottom line

XLV vs FTXH: the short answer

XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and FTXH (First Trust Nasdaq Pharmaceuticals ETF) share a meaningful slice of their top holdings — about 50% by weight.

XLV is cheaper at 0.08% vs 0.6% — a difference of $52 a year per $10,000 invested.

Over five years, XLV returned +8.1% a year vs +6.5% for FTXH.

Updated Nov 19, 2026

XLV vs FTXH side by side

XLVFTXH
TypeETFETF
Fund familySPDR (State Street)First Trust
CategoryHealth Care SectorHealth Care Sector
Expense ratio0.08%0.6%
Annual cost per $10k$8$60
10-yr cost on $10k (prospectus)$103—
Max front loadNoneNone
12b-1 fee0.02%0%
1-yr return+14.5%+24.0%
5-yr return (annualized)+8.1%+6.5%
10-yr return (annualized)+9.8%—
Best quarter+14.5%+18.3%
Worst quarter−12.7%−17.4%
Net assets (fund)$40.6B$36.2M
Number of holdings6551
Portfolio turnover2%35%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearXLVFTXHDifference
2025+14.5%+24.0%−9.5%
2024+2.5%+3.0%−0.5%
2023+2.0%−1.4%+3.4%
2022−2.1%+2.5%−4.6%
2021+25.9%+6.1%+19.8%
2020+13.3%+10.9%+2.4%
2019+20.7%+22.4%−1.7%
2018+6.3%−8.4%+14.6%
2017+21.7%+18.8%+2.9%

Source: Fund prospectus bar charts

Holdings overlap

11 of XLV's top 25 holdings also appear in FTXH's top 25.

Shared top holdings
HoldingXLVFTXH
Eli Lilly & Co16.51%7.77%
Johnson & Johnson10.64%6.96%
AbbVie Inc7.74%7.39%
Merck & Co Inc5.52%7.07%
Amgen Inc3.40%3.18%
Gilead Sciences Inc2.73%2.89%
Pfizer Inc2.39%2.97%
Vertex Pharmaceuticals Inc2.19%3.41%
Bristol-Myers Squibb Co2.05%6.29%
Regeneron Pharmaceuticals Inc1.08%2.72%
Cardinal Health Inc0.97%3.53%

Source: SEC Form N-PORT

XLV top 10

  1. Eli Lilly & Co — 16.51%
  2. Johnson & Johnson — 10.64%
  3. AbbVie Inc — 7.74%
  4. UnitedHealth Group Inc — 6.57%
  5. Merck & Co Inc — 5.52%
  6. Amgen Inc — 3.40%
  7. Thermo Fisher Scientific Inc — 3.24%
  8. Abbott Laboratories — 2.75%
  9. Gilead Sciences Inc — 2.73%
  10. Intuitive Surgical Inc — 2.45%

FTXH top 10

  1. Eli Lilly & Company — 7.77%
  2. Abbvie Inc — 7.39%
  3. Merck & Company Inc — 7.07%
  4. Johnson & Johnson — 6.96%
  5. Bristol-myers Squibb Company — 6.29%
  6. Biogen Inc — 3.84%
  7. Viatris Inc — 3.62%
  8. Cardinal Health Inc — 3.53%
  9. Vertex Pharmaceuticals Inc — 3.41%
  10. Amgen Inc — 3.18%

FAQ

What is the difference between XLV and FTXH?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and FTXH (First Trust Nasdaq Pharmaceuticals ETF) share a meaningful slice of their top holdings — about 50% by weight. XLV is cheaper at 0.08% vs 0.6% — a difference of $52 a year per $10,000 invested.
Which is cheaper, XLV or FTXH?
XLV has the lower expense ratio (0.08%).
Should I own both XLV and FTXH?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.